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Abstract 
There is currently a major controversy surrounding the off-label use of recombinant activated Factor VII (rFVIIa). The 
literature offers at best inconclusive support for its use in the management of bleeding in any situation other than in patients 
with Factor VII deficiency or hemophilia A or B with antibodies to factor VIII or factor IX respectively. This evidence has 
not, however, slowed the growth in off-label prescribing of rFVIIa in other situations including intracranial hemorrhage, 
cardiac surgery, trauma, transplantation and prostatectomy. We argue that the controversy surrounding such off-label use of 
rFVIIa stems in part from different understandings of the purposes and methods of evidence-based medicine (EBM) - in 
particular the use of gross, proxy outcomes such as mortality to determine the effectiveness of an intervention. We then 
argue that clinical impression and expert opinion should not be dismissed outright on the basis of inconclusive evidence of 
ineffectiveness. Those who advocate its continued use, however, have a responsibility to demonstrate the benefits that may 
be missed in current manifestations of EBM. We suggest that the only justified verdict in the case of rFVIIa is currently 'Not 
Proven'. 
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Introduction 
 
Readers of general medical journals will have recently 
seen a series of articles, editorials and letters in a number 
of prominent publications arguing the pros and cons of the 
‘off-label’ use of recombinant Factor VIIa (rFVIIa) for the 
treatment of major hemorrhage [1-5]. There is compelling 
evidence to support the use of rFVIIa for the control of 
bleeding in very rare cases of Factor VII deficiency and in 
the rare cases of hemophilia with inhibitors to Factor VIII 
or IX. For these uses, it has FDA approval. Because of the 
role that Factor VII has in normal hemostasis and 
thrombosis, it has also been used in bleeding associated 
with obstetrics [6], cerebral trauma [7] and other causes of 
intracranial haematoma, cardiac surgery [8], urology [9] 
and general trauma [10]. This logic has led clinicians to an 
enormous increase (over 140-fold) in off-label prescribing 
of rFVIIa in less than a decade, to the extent that 97% of 
its use is now ‘off-label’ [5]. Clinicians who prescribe 
rFVIIa off label probably do so for good reason. There is a 
clear physiological mechanism that would suggest that 
rFVIIa would work in any of these contexts. rFVIIa has 
also been seen to ‘work’ in bleeding patients and there is 
some evidence from controlled studies that rFVIIa can 
reduce hematoma expansion and transfusion requirements 
in some contexts, such as warfarin-associated intracranial 
bleeding [11] and prostatectomy [9]. 
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Evidence-based Medicine 
 
Enter epidemiology and evidence-based medicine (EBM). 
A recent systematic review by Yank et al [4]  suggests 
rFVIIa has no benefit (in terms of reduced mortality) in 
intracerebral hemorrhage, adult cardiac surgery or thoraco-
abdominal trauma and that there may be an increased risk 
of thromboembolism (TE) when it is used to treat 
intracerebral hemorrhage and bleeding in adult cardiac 
surgery. While this review demonstrated some possible 
benefits, (including reduced hematoma expansion in 
cerebral hemorrhage and reduced adult respiratory distress 
syndrome in trauma), the strength of evidence was low for 
most positive outcomes and could have been accounted for 
(at least in part) by publication bias arising from the fact 
that most trials were sponsored by the manufacturer of 
rFVII, Novo Nordisk.  
The accompanying editorial in the Annals of Internal 
Medicine used the results of the systematic review to 
condemn the off-label use of rFVIIa and raised the 
possibility of legal action against “physicians who persist 
in such use in the face of clear evidence of inutility and 
harm (and who) could be subject to civil action by the 
affected patients or their heirs” [2]. Unsurprisingly, the 
review and editorial generated heated responses suggesting 
that clinical demands and impressions would (and should) 
trump the evidence offered and that clinicians would (and 
should) continue to use rFVIIa for off-label indications 
[1,3]. The editors responded [2] that clinicians should ‘rise 
above the “availability heuristic” – the tendency to base 
decisions on the events which are most apparent at the time 
(diminution of bleeding) rather than on more complete 
risk-benefit information.’  
The dispute has hallmarks of what the Harvard 
Business School might distinguish as ‘an EBM classic’ 
[12], a paradigm confrontation between the ‘hard’ and 
‘soft’ extremes of EBM. At the hard end are those who 
insist that the evidence from a systematic review should 
trump clinical experience. At the other end stand clinicians 
who point out that “even if the safety data from existing 
randomized trials do apply…this risk is likely dwarfed by 
the risk of allowing blood loss to continue unabated…All 
procoagulant agents have the risk for potential adverse 
responses, but their individualized risk-benefit profile is 
largely dependant on the clinical context” [1]. So how can 
we progress this debate? In order to do so, we need to 
consider the purposes and methods of EBM. 
EBM deals with outcomes and meta-analyses and 
collective reviews tend to deal with aggregated outcomes. 
While this provides a means for making gross assessments 
of the therapeutic efficacy of the intervention - the limits of 
this approach become clear in the dispute surrounding the 
off-label use of rFVIIa. Some argue that the (proxy) 
outcome of overall mortality should be the principal 
measure upon which the assessment of the effectiveness of 
rFVIIa should be based and should be the thing that guides 
practice, while others are more concerned about the 
immediate clinical effect of rFVIIa - its effect on bleeding. 
 
Intent and proxy outcomes 
 
It thus becomes clear that the influence of intent is 
important in the debate about rFVIIa. What does the 
clinician intend to do at the moment of treatment? What 
does he hope to achieve? In the context of acute bleeding, 
it could be argued that he intends primarily to stop 
bleeding. Whether the patient subsequently then survives 
will depend not simply on the use of rFVIIa, but also on 
co-morbidities related either to the original insult or to the 
effects of hypotension or shock resulting from blood loss. 
According to this view, rFVIIa is only ineffective if it does 
not control bleeding. Mortality, therefore, may not be an 
adequate measure of the effectiveness of this, or any other, 
hemostatic agent.   
This raises questions regarding the use of proxies in 
clinical research and practice. A proxy is a person or thing 
used to represent someone or something else for a 
particular purpose. We often choose outcomes in clinical 
trials, meta-analyses and collective reviews that are proxies 
for the effectiveness of interventions. This means that we 
sometimes use clear and simply measurable outcomes such 
as mortality to tell us whether a particular intervention is 
effective, often without regard for the purpose of the 
intervention. The problem with the use of such proxies is 
that subtle variations of intent can be missed by using 
evidence in this way. Death may follow urgent surgery for 
trauma, but the death might result from many causes 
including infection, prolonged hypotension before the 
surgery, renal failure and may not be an indicator that the 
surgery itself has failed [13]. While this intervention may 
be assessed in terms of its gross outcome (mortality), its 
intent (e.g. controlling acute bleeding) may be missed. 
 
A way forward 
 
So what is the way forward? How do we mediate between 
those concerned with the use of epidemiological outcomes 
as a guide to practice and those more concerned with 
immediate clinical outcomes such as reduced bleeding? 
To resolve this, it might be helpful to bear in mind that 
we are faced with what have been called ‘essentially 
contested concepts’ [14]. Both sides sincerely believe they 
are right and they both have reasons to believe their 
rightness. They are seriously committed to their beliefs and 
there is an element of outrage in the arguments on both 
sides, one invoking legal sanction against the other [2], the 
other responding by invoking clinical obligations and 
necessities [1].  
Many of us are conditioned by the tenets of evidence-
based medicine to accept EBM findings and reject 
anything based on clinical impression. But both evidence-
based medicine and the evidence of clinical observation 
have a place in medicine. Neither of these can be 
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uncontroversially privileged. We consistently rely upon the 
combined and long-enduring experience of generations of 
medical practitioners, but we also accept that we should 
apply the ‘best available’ evidence, even if its outcomes 
may not be directly relevant to the question at hand [15]. 
The fact that both sides ‘know’ that they are right with 
equal conviction shows that neither those advocating the 
use of rFVIIa, nor those condemning it, have access to the 
‘truth’.  There needs to be a balance between clinical 
observation and scientific evidence. Neither have all the 
answers for so complex a praxis as medicine. 
In this case, therefore, rather than condemning those 
who prescribe rFVIIa off-label, we should demand further 
evidence to support or refute their practice. Are there 
certain patients in whom rFVIIa significantly reduces 
bleeding, or are these false impressions encouraged by 
wishful-thinking at critical moments and by the use of 
flawed proxies for blood loss (such as transfusion 
requirements and hematoma expansion)? And are there 
subtle, but clinically significant, measures of control that 
collective reviews and meta-analyses inevitably miss? 
 
 
Conclusion 
 
When clinical observation and scientific knowing come 
into conflict, as they do with the use of rFVIIa, science 
needs to ask “Are we missing something? How could we 
sensitise our investigations to the intuitions of 
practitioners?” The Scottish legal verdict of Not Proven is 
wise in agreeing that no other verdict is possible at this 
moment, but that a re-trial would be possible, should new 
evidence emerge. The verdict in the case of rVIIa surely 
remains Not Proven. 
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